Lenneke F J van Groningen
Overview
Explore the profile of Lenneke F J van Groningen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Groningen L, van Dorp S, Bremmers M, Fazel S, Roeven M, Blijlevens N, et al.
Leuk Lymphoma
. 2024 Mar;
65(7):950-957.
PMID: 38520720
Background: Acute gastro-intestinal graft--host disease (GI-GVHD) and non-relapse mortality (NRM) after allogeneic HCT are closely related to loss of microbial diversity and intestinal dominance by single taxa resulting from the...
2.
de Mooij C, van Groningen L, Molendijk E, Wardill H, van der Velden W, Blijlevens N
Clin Infect Dis
. 2022 Nov;
76(6):1152-1153.
PMID: 36370047
No abstract available.
3.
Coolen J, Wolters F, Tostmann A, van Groningen L, Bleeker-Rovers C, Tan E, et al.
J Clin Virol
. 2021 Oct;
144:104993.
PMID: 34619382
During the course of the SARS-CoV-2 pandemic reports of mutations with effects on spreading and vaccine effectiveness emerged. Large scale mutation analysis using rapid SARS-CoV-2 Whole Genome Sequencing (WGS) is...
4.
de Mooij C, van Groningen L, de Haan A, Biemond B, Bakker M, van der Velden W, et al.
Trials
. 2020 Nov;
21(1):948.
PMID: 33225965
Background: Since decades, fever and infections have been the most important complications of intensive chemotherapy and hematopoietic stem cell transplantation (HSCT) in the treatment of hematologic malignancies. Neutropenia has long...
5.
de Kort E, de Lil H, Bremmers M, van Groningen L, Blijlevens N, Huls G, et al.
PLoS One
. 2019 Mar;
14(3):e0213913.
PMID: 30897127
Low plasma CsA concentrations (<300-350 ng/mL) early following allogeneic hematopoietic stem cell transplantation (HSCT) is associated with an increased risk of developing acute graft-versus-host disease (aGvHD). Nevertheless, the current optimal...
6.
Groth C, van Groningen L, Matos T, Bremmers M, Preijers F, Dolstra H, et al.
Biol Blood Marrow Transplant
. 2018 Nov;
25(4):712-719.
PMID: 30399420
Effective therapies for treating patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD), particularly strategies that reduce the duration of immunosuppression following remission, are urgently needed. The investigated immunotoxin combination consists of a...
7.
van Groningen L, Liefferink A, de Haan A, Schaap N, Donnelly J, Blijlevens N, et al.
Biol Blood Marrow Transplant
. 2015 Sep;
22(1):179-82.
PMID: 26386320
Steroid-refractory acute graft-versus-host disease (aGVHD) remains an important cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). A protocol on the management of aGVHD was introduced in our...
8.
van Groningen L, Preijers F, Jansen J, Hebeda K, van der Velden W
Ann Hematol
. 2013 Feb;
92(9):1287-8.
PMID: 23404583
No abstract available.